Recent Research Analysts’ Ratings Changes for argenex (ARGX)

A number of research firms have changed their ratings and price targets for argenex (NASDAQ: ARGX):

• 10/27/2026 – argenex had its price target lowered by Citigroup from $1,301.00 to $1,232.00. They now have a “buy” rating on the stock.
• 10/25/2026 – argenex was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/23/2026 – argenex had its price target raised by Morgan Stanley from $1,140.00 to $1,190.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – argenex had its price target lowered by Guggenheim from $1,185.00 to $1,120.00. They now have a “buy” rating on the stock.
• 10/23/2026 – argenex had its price target lowered by Wells Fargo & Company from $1,356.00 to $1,336.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – argenex had its price target raised by Robert W. Baird from $823.00 to $861.00. They now have a “neutral” rating on the stock.
• 10/21/2026 – argenex had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 10/20/2026 – argenex had its price target lowered by Royal Bank Of Canada from $1,100.00 to $1,025.00. They now have an “outperform” rating on the stock.
• 10/17/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/14/2026 – argenex had its price target raised by Wells Fargo & Company from $1,355.00 to $1,356.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – argenex had its price target lowered by Oppenheimer from $1,100.00 to $1,038.00. They now have an “outperform” rating on the stock.
• 10/9/2026 – argenex had its “neutral” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 10/9/2026 – argenex had its “buy” rating reaffirmed by DZ Bank.
• 10/9/2026 – argenex had its price target lowered by Robert W. Baird from $932.00 to $823.00. They now have a “neutral” rating on the stock.
• 10/8/2026 – argenex had its price target lowered by Wedbush from $1,150.00 to $1,130.00. They now have an “outperform” rating on the stock.
• 10/8/2026 – argenex had its “buy” rating reaffirmed by Sanford C. Bernstein.
• 9/25/2026 – argenex had its “buy” rating reaffirmed by The Goldman Sachs Group.
• 9/19/2026 – argenex was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/14/2026 – argenex had its “buy” rating reaffirmed by Jefferies Financial Group.
• 9/7/2026 – argenex had its “buy” rating reaffirmed by Barclays.
• 9/6/2026 – argenex was upgraded by Wall Street Zen from “hold” to “buy”.

argenex Price Performance

Shares of NASDAQ ARGX opened at $874.97 on Tuesday. The firm has a fifty day moving average price of $940.31 and a 200-day moving average price of $855.14. The stock has a market cap of $55.03 billion, a PE ratio of 30.53, a price-to-earnings-growth ratio of 0.82 and a beta of 0.44. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75.

argenex (NASDAQ:ARGX) last released its earnings results on Friday, October 23rd. The company reported $7.80 earnings per share for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. The company had revenue of $1.75 billion for the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. On average, research analysts expect that argenex SE will post 28.63 EPS for the current year.

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.